Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...

Shares Biotechnology ETF offers efficient, diversified exposure to the sector's revival, balancing risk and cost for ...

At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.

Scinai Immunotherapeutics (NASDAQ: SCNI) reported first quarter 2025 financial results, posting $586K in revenue, up from zero in the prior-year per ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Discover 9 promising small molecule drug discovery companies that recently raised funding for their potentially breakthrough ...

Just a few months after raising $200 million in third-round financing, immunology specialist Zenas ... acceleration in the number of biotech companies seeking public listings after a two-year ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Through a combination of academic rigor, innovative AI applications, and cross-disciplinary collaboration, Dr. Ravikanth ...

The numbers for first quarter 2025 biotech financings are in and they ... with investors continuing to favor later-stage companies that have clinical data. Finding the best analytics tools for ...

From my colleague Adam Feuerstein: French drug maker Sanofi is acquiring the small biotech Vigil Neuroscience for $470 ...

Here's our list of the leaders in Massachusetts tech, biotech and climate tech who aren't just surviving, but moving their ...